PL2043661T3 - Zastosowanie tylwalozyny jako środka przeciwwirusowego - Google Patents

Zastosowanie tylwalozyny jako środka przeciwwirusowego

Info

Publication number
PL2043661T3
PL2043661T3 PL07766205T PL07766205T PL2043661T3 PL 2043661 T3 PL2043661 T3 PL 2043661T3 PL 07766205 T PL07766205 T PL 07766205T PL 07766205 T PL07766205 T PL 07766205T PL 2043661 T3 PL2043661 T3 PL 2043661T3
Authority
PL
Poland
Prior art keywords
tylvalosin
antiviral agent
antiviral
agent
Prior art date
Application number
PL07766205T
Other languages
English (en)
Inventor
Albert Philip Adrian Mockett
Thomas David Kay Brown
Amanda Denise Stuart
Original Assignee
Eco Animal Health Ltd
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613952A external-priority patent/GB0613952D0/en
Priority claimed from GB0621782A external-priority patent/GB0621782D0/en
Application filed by Eco Animal Health Ltd, Cambridge Entpr Ltd filed Critical Eco Animal Health Ltd
Publication of PL2043661T3 publication Critical patent/PL2043661T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07766205T 2006-07-13 2007-07-13 Zastosowanie tylwalozyny jako środka przeciwwirusowego PL2043661T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0613952A GB0613952D0 (en) 2006-07-13 2006-07-13 Antiviral agent
GB0621782A GB0621782D0 (en) 2006-11-01 2006-11-01 Antiviral agent
EP07766205.4A EP2043661B1 (en) 2006-07-13 2007-07-13 Use of tylvalosin as antiviral agent
PCT/GB2007/002620 WO2008007104A1 (en) 2006-07-13 2007-07-13 Use of tylvalosin as antiviral agent

Publications (1)

Publication Number Publication Date
PL2043661T3 true PL2043661T3 (pl) 2015-03-31

Family

ID=38519613

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07766205T PL2043661T3 (pl) 2006-07-13 2007-07-13 Zastosowanie tylwalozyny jako środka przeciwwirusowego

Country Status (15)

Country Link
US (2) US9066964B2 (pl)
EP (1) EP2043661B1 (pl)
JP (1) JP5232781B2 (pl)
KR (1) KR101413274B1 (pl)
BR (1) BRPI0714374A2 (pl)
CA (1) CA2657275C (pl)
CY (1) CY1115847T1 (pl)
DK (1) DK2043661T3 (pl)
ES (1) ES2526817T3 (pl)
MX (1) MX2009000393A (pl)
PL (1) PL2043661T3 (pl)
PT (1) PT2043661E (pl)
RU (1) RU2412710C2 (pl)
SI (1) SI2043661T1 (pl)
WO (1) WO2008007104A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1021434B1 (nl) 2013-11-20 2015-11-20 Proviron Holding Veevoeder aangerijkt met een combinatie van monoglycerides.
CN103923140B (zh) * 2014-04-14 2016-06-15 宁夏泰瑞制药股份有限公司 一种酒石酸乙酰异戊酰泰乐菌素的制备方法
CA2948832A1 (en) 2014-05-13 2015-11-19 Microbial Discovery Group, Llc Direct-fed microbials and methods of their use
US10335440B2 (en) 2016-02-29 2019-07-02 Microbial Discovery Group, Llc Direct-fed microbials
US11627741B2 (en) 2018-09-28 2023-04-18 Microbial Discovery Group, Llc Microorganisms for plant pathogen inhibition
WO2020241759A1 (ja) * 2019-05-29 2020-12-03 学校法人帝京大学 インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤
JP7497790B2 (ja) * 2019-12-27 2024-06-11 国立大学法人北海道大学 豚コレラの治療及び／又は予防剤
KR102449133B1 (ko) * 2021-05-10 2022-09-28 전북대학교산학협력단 항바이러스 조성물 및 그의 제조방법
CN115896217A (zh) * 2022-12-16 2023-04-04 内蒙古中牧生物药业有限公司 一种提高泰万菌素发酵水平的补料工艺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1978409A (en) * 1934-05-01 1934-10-30 Raalte Company Van Mechanism and mechanical method for making runproof or run-re-sistant full-fashionedhosiery
US4092473A (en) 1975-08-01 1978-05-30 Sanraku Ocean Co., Ltd. Tylosin derivatives and their manufacturing process
GB0025556D0 (en) * 2000-10-18 2000-12-06 Eco Animal Health Ltd Treatment and prophylaxis of disease and infections of pigs and poultry
GB0315629D0 (en) 2003-07-03 2003-08-13 Eco Animal Health Ltd New uses for antibiotic

Also Published As

Publication number Publication date
US9066964B2 (en) 2015-06-30
DK2043661T3 (en) 2015-01-05
ES2526817T3 (es) 2015-01-15
KR101413274B1 (ko) 2014-07-08
CY1115847T1 (el) 2017-01-25
CA2657275C (en) 2013-09-24
KR20100014221A (ko) 2010-02-10
RU2009104022A (ru) 2010-08-20
US9649324B2 (en) 2017-05-16
US20150313929A1 (en) 2015-11-05
RU2412710C2 (ru) 2011-02-27
EP2043661B1 (en) 2014-10-01
JP5232781B2 (ja) 2013-07-10
CA2657275A1 (en) 2008-01-17
US20100010080A1 (en) 2010-01-14
EP2043661A1 (en) 2009-04-08
BRPI0714374A2 (pt) 2013-05-14
SI2043661T1 (sl) 2015-02-27
MX2009000393A (es) 2009-01-29
PT2043661E (pt) 2014-12-22
WO2008007104A1 (en) 2008-01-17
JP2009542790A (ja) 2009-12-03

Similar Documents

Publication Publication Date Title
IL196583A0 (en) Antiviral use of cationic surfactant
ZA201003234B (en) Use of oligonucleotides with modified bases as antiviral agents
PL2335782T3 (pl) Zastosowanie kompozycji zawierającej HFCO-1233zd
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINS
GB0709791D0 (en) Antiviral agents
GB0707000D0 (en) Antiviral agents
IL202139A0 (en) Heteroaryl substituted thiazoles and their use as antiviral agents
PL2043661T3 (pl) Zastosowanie tylwalozyny jako środka przeciwwirusowego
EP2120952A4 (en) ANTIVIRAL COMPOUNDS AND METHOD FOR THEIR USE
HK1125371A1 (en) Substituted arylsulfonamides as antiviral agents
GB0613952D0 (en) Antiviral agent
IL196606A0 (en) Use of escin
HK1161122A1 (en) Use of 24-norudca 24-norudca
EP2062892A4 (en) AGENT ENHANCING HYPERTENSION
GB0805264D0 (en) Antiviral agents
GB0803707D0 (en) Antiviral agent
EP2030629A4 (en) AGENT FOR IMPROVING LIPID METABOLISM
EP1931370A4 (en) USE OF DES-ASPARTATE-ANGIOTENSIN I
EP2060263A4 (en) AGENT FOR IMPROVING LIPID METABOLISM
EP2127675A4 (en) ANTIVIRAL MEDIUM
GB0700179D0 (en) Use of epoxidised compounds
GB0703514D0 (en) Use of riboflavin
ZA201003156B (en) Use of liquefied-gas compositions
GB0621782D0 (en) Antiviral agent
GB0612370D0 (en) Uses of (S)-clenbuterol